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Neuromyotonia: Potassium channelopathy  
or non ionic disease?
G. Serratrice
CHU La Timone, Marseille, France
The  early  pathophysiologic  study  showed  increasing  evi-
dence that autoimmunity is implicated in the pathogenesis of neu-
romyotonia. Antibodies to voltage gated potassium channel were 
detected in the serum of patients who had peripherical nerves hy-
perexcitability and also Morvan’s disease or limbic encephalitis. 
These discoveries offered new approaches to treatments.
Recently, antibodies previously attributed to VGKC rec-
ognise 2 surface antigens LGI1 and CASPR2 into the VGKC 
complex. Finally, VGKC antibodies are directed to 2 proteins 
the first one is a key hippocampic protein containing pre and 
post synaptic proteins. The second one CASPR2 is an hippoc-
ampic and paranodal protein. There clinical significance is dif-
ferent: hyperexcitability limbic encephalitis without thymoma 
for LGI1, hyperexcitability Morvan limbic encephalitis and fre-
quent thymoma for CASPR2.
In  conclusion,  the  term  NMT  -  LE  - VGKC  should  be 
changed to NMT- LE with LGI1 and CASPR2 antibodies and 
classified as auto immune synaptic disorders.
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Crossing barriers: how medical doctors and 
researchers can partner with Advocacy Groups
L. Feld
Periodic Paralysis Association Vice President, Orlando, Florida, USA
Disease advocacy groups (DAGs) by and large arise in chron-
ic or devastating diseases for which persistent unmet needs exist. 
Patients seek DAGs for a variety of reasons, but most importantly 
to find immediate psychological, diagnostic, and therapeutic cop-
ing mechanisms. Factors that drive their continued involvement 
include hope for finding a permanent cure and an altruistic desire 
to increase awareness and share their experiences to help others 
in similar need. In doing so, they frequently establish a conduit 
to world experts in their rare disorder, and where needed, better 
define disease characteristics and management.
DAGs provide help to their members in a variety of ways:
1)  offer web-based, easily accessible and medically reliable 
information to patients about their condition;
2)  offer a means of members to interact either through email 
list serves, blogs, or message boards;
3)  organize annual meetings for members, whereby disease 
experts and members can interact face to face;
4)  offer a virtual interface between medical experts and their 
membership via on-line “Ask The Experts”;
5)  potentiate blood banking and genetic research by gathering 
relatively large numbers of patients in one repository;
6)  organize and galvanize scientific and medical experts to re-
search the condition;
7)  motivate experts to help the DAG members.
Physicians  are  the  ultimate  backbone  of  any  DAG  that 
wishes to provide more than psychosocial coping modalities 
for  their  members.  Members  ultimately  seek  credible  medi-
cal knowledge as the best chance to navigate their illness and 
achieve normalcy in their lives. The fundamental ways in which 
physicians can support a DAG is by being actively available to 
attend DAG member conferences, answer member questions, 
contribute to website content, and cooperate to establish con-
sensus protocols for diagnosis and therapy, and work with each 
other to find meaningful diagnostic modalities and treatments.
Barriers to a DAG’s achieving its mission are many. DAGs 
often lack funding, frequently suffer from disinterest by a majority 
of the few medical experts interested in their disease, are some-
times hurt by splinter groups for the same disease fragmenting 
limited resources, and may find themselves caught between politi-
cal or personality differences among their medical experts.
Barriers  to  physician  participation  in  DAGs  are  many: 
competition for time of the physician by other diseases, lim-
ited time to deal with individual patient concerns, medico-legal 
uncertainties of interactions with DAG members, lack of rec-
ognition or peer reviewed publication credit for writing web-
site content, cost of travel to meetings, having only non-clinical 
research interest, and knowledge in only a limited aspect of a 
disease in question.
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Current therapeutic guidelines in Duchenne 
Muscular Dystrophy to prolong life
V. Riccio, I. Riccio, F. Gimigliano, D. Riccardi, G. Riccardi, 
R. Gimigliano, L. Politano1, G. Nigro1, G. Duport1, Y. Rideau1
Dipartimento di Scienze Ortopediche, Traumatologiche, Riabilitative e 
Plastico Ricostruttive Second University of Naples; 1 Institut Duchenne 
Italia (IDI), Naples, Italy
Duchenne’s myopathy is an X-linked disease with well de-
fined evolutionary phases, characterized by degradation of the 